The Oncology Institute, Inc.
TOI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $137 | $120 | $104 | $100 |
| % Growth | 14% | 14.7% | 4.1% | – |
| Cost of Goods Sold | $118 | $102 | $87 | $86 |
| Gross Profit | $19 | $18 | $17 | $15 |
| % Margin | 13.9% | 14.6% | 16.5% | 14.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $25 | $0 | $25 | $25 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $29 | $2 | $2 |
| Operating Expenses | $27 | $29 | $27 | $27 |
| Operating Income | -$8 | -$11 | -$10 | -$12 |
| % Margin | -5.9% | -9.4% | -9.5% | -11.9% |
| Other Income/Exp. Net | -$8 | -$6 | -$10 | -$1 |
| Pre-Tax Income | -$17 | -$17 | -$20 | -$13 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$17 | -$17 | -$20 | -$13 |
| % Margin | -12.1% | -14.2% | -18.8% | -13.1% |
| EPS | -0.14 | -0.15 | -0.21 | -0.14 |
| % Growth | 6.7% | 28.6% | -50% | – |
| EPS Diluted | -0.14 | -0.15 | -0.21 | -0.14 |
| Weighted Avg Shares Out | 975 | 932 | 77 | 76 |
| Weighted Avg Shares Out Dil | 975 | 932 | 77 | 76 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $2 | $6 | $1 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$13 | -$9 | -$12 | -$10 |
| % Margin | -9.4% | -7.9% | -11.7% | -10.3% |